All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
The FDA grants acalabrutinib Priority Review for the possible treatment of relapsed/refractory Mantle Cell Lymphoma
Bookmark this article
On 2nd August 2017, a New Drug Application (NDA) for acalabrutinib was granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL).
This announcement follows acalabrutinib being awarded Breakthrough Therapy Designation (BTD) only one day previously; read more here. Similar to the BTD submission, the NDA is supported partly by results from the phase II ACE-LY-004 trial (NCT02213926).
It is expected that the FDA will make a final approval decision for acalabrutinib in the setting of R/R MCL in early 2018.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
28 votes - 86 days left ...
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox